


Understanding Value from the Payer's
Perspective: the NHS Experience – *Karl
Claxton*, Professor of Economics, Centre for
Health Economics, University of York

Prepared for: **Differential Pricing Based on Value:
Progressing the Discussion from Theory to Practice**


Videoconference hosted by: Center for Global Development Europe

March 23, 2020
2:00-4:00PM

What is a value based price?



UK estimates of health opportunity costs




Lomas J, Martin S and Claxton K. Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13. Forthcoming, Value in Health 2019


Martin S, Lomas J and Claxton K. How effective is marginal health care expenditure? Evidence from England for 2003/04 to 2012/13. Submitted to social Science and Medicine

Claxton K, Lomas J, Martin S. The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics. 2018 Apr 2. Available from, DOI: 10.1002/hec.3650

Incentives for future innovation?




TA391 Cabazitaxel for prostate cancer




- Consumer surplus does not rise above zero due to high approval norm
- Consumer surplus will be lower if initial approval within the Cancer Drugs Fund taken in to account


A global problem



Mechanisms for price discrimination



Mechanisms for price discrimination



Mechanisms for price discrimination

